|Videos|October 31, 2016

Zika in the US—Not Just a Florida Problem

Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, discusses the prevalence of Zika virus infections in New York City.

Interview Transcript (slightly modified for readability)

“At this point Zika is everywhere. We think that the only place that there is local transmission through mosquitoes is in South Florida; [however], every state in the country has had travel-related cases of Zika. Because of that, every state in the country has to be prepared to take care of a patient with Zika, and particularly pregnant women.

New York [City] is a very densely populated city. We’ve seen more cases of travel-related Zika in New York City than in most states across the country. Already at this point we’ve had difficulty with resource allocation when taking care of pregnant women, in particular, in New York, and this is only going to increase.

In New York City, we’ve seen more than 600 cases of travel-related Zika. Across the United States there have been around 4000 so far. We’ve had many cases of pregnant women who’ve had Zika, and a number of cases of infants [who were] born with birth defects.”

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

October 23rd, 2026

Household Contacts Drive Most Hepatitis B Exposures in Young Children

Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.

October 24th, 2026

Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases

Exploratory SCORPIO-PEP data presented at IDWeek 2026 show household contacts with breakthrough COVID-19 on ensitrelvir had lower peak viral RNA and fewer severe symptoms than placebo recipients.

John H. Rex, MD, chief medical officer of F2G

October 23rd, 2026

Oral Olorofim Noninferior to AmBisome in Phase 3 OASIS Trial

Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.

Helio S. Sader, MD, PhD (Credit: JMI Labs)

October 23rd, 2026

Aztreonam-Avibactam Holds Activity as MBL-Producing CRE Rise in US

MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.

October 23rd, 2026

Bictegravir/Lenacapavir Well Tolerated in HIV With Comorbidities

Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.

Varshini Thiruvadi, MD (Credit: LinkedIn)

October 23rd, 2026

Isavuconazole Has Lowest Hepatotoxicity Signal Among Azoles in FAERS

Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.

October 23rd, 2026

Zoliflodacin Holds Gonorrhea Cure Rates in Chlamydia Coinfected Patients

Data being presented at IDWeek 2026 show zoliflodacin maintains high gonorrhea cure rates in patients co-infected with chlamydia. David Altarac, MD, discusses the therapy and the study being presented at the conference.

October 22nd, 2026

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.